SBIR/STTR Research Award

METHOD FOR EARLY SCREENING OF DIABETIC RETINOPATHY

Award identifier d5c76385cb5c1371bed5b75694d762674f4ace29a4e18c02e51142cc53c6664cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,961

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
OPTICAL INSIGHTS, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION ( Investigator's Abstract): Gastroesophageal reflux disease (GERD) is a physical condition resulting from an inability of the lower esophageal sphincter (LES) to prevent reflux of stomach acids into the esophagus. This disease along with its associated problems is presenting in increasing numbers across the general population and current non-surgical options, in addition to being expensive, treat only the symptoms as opposed to correction of the defect. Additionally, there is increasing evidence that GERD may lead to significant increases in the risk for cancer development. The focus of this research is to develop a novel enodscopic-based laser delivery system for treatment of GERD. In this phase I study the investigators propose to develop and test a laser delivery catheter able to create a single homogeneous thermal lesion along the length of the LES. Innovative features of the catheter allow it to thermally treat the muscular layer while preventing damage to the esophageal mucosa. Studies are planned to allow optimization of the catheter's delivery parameters in vitro followed by in vivo testing in a porcine model. The investigators plan to demonstrate feasibility by assessing the system in terms of its efficacy in augmenting barrier function by improving gastric yield pressure. PROPOSED COMMERCIAL APPLICATION: It is estimated that 33% of the adult population experience heartburn at least once a month and approximately 14 million Americans, or 7% of the adult population, suffer from gastroesophageal reflux disorder (GERD). The current annual worldwide market for drugs used to treat (GERD) is approximately $14 billion. Of the 14 million GERD suffers in the U.S., only 70,000 elected for corrective invasive surgery. An effective non-surgical alternative would significantly increase the number of patients seeking permanent correction.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.